After years of experimentation, AI in healthcare and life sciences has crossed a regulatory threshold. Global regulators are no longer observers from the sidelines; they are now defining how AI must be designed, governed, monitored, and updated throughout its lifecycle. The FDA has issued explicit lifecycle guidance for AI-enabled devices, the EMA is driving a multi-year AI workplan, and the WHO has introduced ethical guardrails for large multimodal models (LMMs).
For companies across pharma, biotech, medtech, and digital health, the message is unmistakable: Regulatory Technology (RegTech) isn’t a support function anymore; it’s the backbone of compliant, scalable AI adoption. RegTech is shifting from a nice-to-have automation to a central capability that keeps products audit-ready, submissions faster, and risk under control across global markets.
Let’s break down what’s changing and why RegTech is becoming one of the most strategic investments in HLS.
What RegTech actually means in HLS
RegTech combines AI, automation, NLP, and robust data governance to modernize regulatory processes end-to-end. In practice, it enables things like:
Automated regulatory submissions (investigational new drug application (IND), new drug applications (NDA), marketing authorization applications (MAA), and premarket approval (PMA)
Continuous validation and lifecycle monitoring for AI/ML models
Automated pharmacovigilance with audit-ready case handling
Data lineage, quality checks, bias assessment, and explainability
Vendor and third-party model risk management
When implemented effectively, RegTech shifts teams from reactive, checklist-driven tasks to proactive, real-time assurance that scales across programs and geographies.
Regulatory momentum: FDA, EMA, WHO
FDA: In January 2025, the FDA issued draft guidance for AI-enabled device software functions, detailing what sponsors should include in marketing submissions and how to manage risk across the total product lifecycle (TPLC). The guidance highlights lifecycle documentation (intent, data, performance), post-market monitoring, and predetermined change control plans (PCCPs) for adaptive algorithms.
EMA: EMA and the heads of medicines agencies adopted a multi-annual AI Workplan to 2028, outlining four pillars: guidance and product support, tools and technology, collaboration and training, and structured experimentation, and finalized a reflection paper on AI in the medicinal product lifecycle (adopted September 2024).
WHO: WHO’s guidance on the ethics and governance of LMMs in health provides more than 40 recommendations, emphasizing fairness, transparency, accountability, and the risks of bias, inaccuracy, and automation bias, especially in low-resource settings.
How AI-driven RegTech transforms compliance
Intelligent regulatory submissions
AI/NLP can read large volumes of clinical, safety, and manufacturing data to assemble submission-ready content, extract required fields, flag inconsistencies, and format dossiers to regional templates. With the FDA setting explicit expectations for lifecycle documentation and PCCPs, and the EMA signaling continued guidance and experimentation, automated submission assembly is becoming a strategic capability that reduces cycle time, improves quality, and standardizes evidence across affiliates.Continuous validation and model lifecycle governance
Traditional CSV is periodic and document-heavy. RegTech enables continuous validation: real-time model performance monitoring, drift detection, retraining event logging, and traceable change control mapped to TPLC expectations. This is essential for AI embedded in diagnostics, PV case triage, quality decisions, and manufacturing release, where deviations must be detected, explained, and remediated quickly.Enhanced pharmacovigilance and post-market monitoring
Automation accelerates case intake and triage, standardizes signal detection, and creates immutable audit-trails that feed QMS and regulatory submissions. Lifecycle oversight of AI used in safety or clinical decision support is a recurring theme across FDA and EMA signals; RegTech turns these expectations into operational dashboards, alerts, and documented actions that withstand inspection.Data governance, traceability, and ethical AI
WHO’s guidance underscores the importance of data representativeness, transparency, and accountability. RegTech capabilities, including dataset registries, lineage, data use logs, bias/fairness testing, and explainability artifacts, help teams demonstrate that training data reflect the intended populations and that models behave equitably across subgroups. Both regulators and payers increasingly request this evidence.Third-party model risk management
As organizations integrate vendor models and foundation models, governance must extend beyond the firewall. RegTech supports supplier qualification, model disclosures, audit rights clauses, performance and incident monitoring, and documentation for retraining and versioning, aligning with EU and EMA expectations for responsible AI adoption.
Strategic shift: compliance as capability
Treating compliance as a strategic capability yields tangible advantages: faster market entry through lifecycle-ready dossiers, improved regulator and partner trust via transparent, auditable systems, scalable global operations, harmonized controls across FDA-, EMA-, and WHO-aligned jurisdictions, and a stronger reputation for ethical, explainable, auditable AI. Just as importantly, leadership gains a real-time view of regulatory risk and readiness across portfolios, turning compliance data into decisions about where to invest, how to accelerate, and when to remediate.
Human-in-the-loop governance
Despite advances in automation, human oversight remains central. Regulators expect clear accountability for AI-assisted decisions, explainability of outputs, and documented validation and monitoring. WHO stresses human autonomy and responsible governance; FDA emphasizes traceability and post-market performance; EMA prioritizes capability-building and structured experimentation. Effective RegTech operationalizes a Human-in-the-Loop model, where AI augments workflows, but expert reviewers validate, interpret, and approve actions, and every step is logged for inspection.
Road ahead: intelligent compliance
The next wave will be shaped by regulatory-aware platforms that auto-map new obligations into workflows, AI-powered audit dashboards with live posture and evidence gaps, pre-certified models, and regulatory sandboxes (particularly in the EU/UK) that de-risk adoption, and federated data-governance ecosystems aligned with WHO’s principles of transparency and equity. Firms that build these capabilities early will shorten feedback loops between development, quality, and regulatory, and convert compliance into a durable competitive advantage.
Conclusion
AI is reshaping how innovation happens and how it is governed. RegTech sits at the center of this transition, turning compliance from obligation into enabler: accelerating development, strengthening quality, and building trust. With clear signals from FDA (TPLC, PCCPs, transparency), EMA (AI Workplan and Reflection Paper), and WHO (ethical, equitable AI), the imperative for AI-enabled RegTech is now. The organizations that embed intelligent, auditable compliance as a strategic layer will lead the next era of HLS innovation and market access.
Reference:
https://www.ema.europa.eu/en/news/artificial-intelligence-workplan-guide-use-ai-medicines-regulation